Clinical trials: Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes Mellitus (T2DM)
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK.
- Trial name
- NCT05761301
- Testing
- ALN-KHK
- Where
- 15 sites in United States, Canada
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Diabetes Mellitus Type 2
Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy
This study is designed to assess the potential difference in Fasting Plasma Glucose (FPG) lowering efficacy between the two DPP-4 inhibitors vildagliptin and sitagliptin, both after a two weeks treatment on top of metformin.
- Trial name
- FPG-VISIT (NCT01398592)
- Testing
- Vildagliptin, Sitagliptin
- Where
- 15 sites in Germany
- Volunteers
- 187 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
A Phase 2 study with two cohorts of differing doses designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MEDI0382 in patients with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT03244800
- Testing
- MEDI0382
- Where
- 5 sites in Germany
- Volunteers
- 65 people
- Sponsor
- MedImmune LLC
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes
GSK189075 is intended for use as a single treatment or in combination with other treatments for tye 2 diabetes mellitus (T2DM). Metformin is widely used in Europe and the USA for the treatment of T2DM.
- Trial name
- NCT00376038
- Testing
- GSK189075 oral tablets, metformin tablets
- Where
- Mexico
- Volunteers
- 13 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus With Circulatory Complciation
Association of Carbamylated HDL and CAD in T2DM Patients
This is an observational cross-sectional study aimed at investigating the alterations of the carbamylated-HDL levels in T2DM patients, and comparing the concentration of carbamylated-HDL between the T2DM patients with CAD and…
- Trial name
- NCT04390711
- Testing
- High density lipoprotein isolation, detection and in-vitro study.
- Where
- China
- Volunteers
- 282 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Diabetes Mellitus, Type 2
Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)
To investigate the glycosylated hemoglobin (HbA1c) control of Glimepiride (AMARYL) as OAD initiation mono-therapy in type 2 diabetic patients in China.
- Trial name
- GREAT (NCT00908921)
- Testing
- GLIMEPIRIDE
- Where
- China
- Volunteers
- 391 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2, Obesity
A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.
- Trial name
- NCT07172867
- Testing
- HT-6184, Semaglutide 1 mg
- Where
- United Arab Emirates
- Sponsor
- Halia Therapeutics, Inc.
Diabetes, Type 2 Diabetes (T2DM)
CGM Use in Non-insulin Patients With DM2
The U.S. Food and Drug Administration (FDA) has approved multiple Continuous Glucose Monitoring (CGM) devices from different manufacturers to be used as an aide in patients with type 1 and type 2 diabetes who require medications…
- Conditions
- Diabetes, Type 2 Diabetes (T2DM), Obesity Type 2 Diabetes Mellitus, Non Insulin Dependent Diabetes Mellitus
- Trial name
- CGM-DWI (NCT07128342)
- Testing
- CGM Group, FSBG group
- Volunteers
- 100 people
- Sponsor
- Milwaukee VA Medical Center
Type 2 Diabetes Mellitus
Community Health Workers in Diabetes Care in American Samoa
As type 2 diabetes prevalence increases in the United States, the burden of diabetes falls more on groups with greater barriers to care, such as language and cultural differences, and lower economic resources.
- Trial name
- DCAS (NCT00850824)
- Testing
- Community Health Worker home visits
- Where
- American Samoa
- Volunteers
- 268 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Food Insecurities, Cardiometabolic Comorbidities
Human Immunodeficiency Virus (HIV) Food Insecurities
The objectives of this study are to better understand how FI (food insecurities) contributes to the development of cardiometabolic comorbidities among PWH (People with HIV) and to test a novel bilingual FI intervention designed…
- Conditions
- Food Insecurities, Cardiometabolic Comorbidities, HIV, PreDiabetes
- Trial name
- NCT04943861
- Testing
- weCare/Secure, Usual Care
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Wake Forest University Health Sciences
Type 2 Diabetes Mellitus
ET-blockade and Exercise Induced Blood Flow in T2DM
The purpose of this study is to establish the effect of ET blockade on the acute exercise induced blood flow and endothelial function in subjects with T2DM.
- Trial name
- NCT01779596
- Testing
- Bosentan
- Where
- Netherlands
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
An Open Label, Balanced, Randomized, Single dose, Two treatment, Two sequence, Two period, two way crossover, Oral Bioequivalence Study of test product of Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet and…
- Trial name
- NCT07266766
- Testing
- Empagliflozin / Metformin HCl XR Tablets, Synjardy® XR (empagliflozin and metformin hydrochloride extended-release Tablets)
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Humanis Saglık Anonim Sirketi
T2DM (Type 2 Diabetes Mellitus)
Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets
This is a single-center, randomized, open-label, two-period, two-sequence crossover bioequivalence study under fed conditions. The primary objective is to evaluate the bioequivalence of a single oral dose of the test formulation…
- Trial name
- NCT07519265
- Testing
- Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 1, Chiglitazar tablet, dose 1, Metformin extended-release tablet, dose 1
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Periodontitis, Type 2 Diabetes Mellitus (T2DM)
Para-Probiotic Oral Care in Periodontal Patients With Type 2 Diabetes
This randomized controlled clinical trial aims to evaluate the effectiveness of a para-probiotic-based oral care protocol in improving periodontal health and glycemic control in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- PPDM2 (NCT07069166)
- Testing
- Para-probiotic oral care, Chlorhexidine oral care
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- University of Pavia
Type 2 Diabetes Mellitus (T2DM), Irreversible Pulpitis
Complete Pulpotomy and Root Canal Treatment Patients With Irreversible Pulpitis With Type 2 Diabetes Mellitus
there is limited endodontic research on the effects of DM on pulp tissues. Diabetic human and animal histological research have demonstrated decreased wound repair, chronic pulp inflammation and reduced dentin bridge formation.
- Trial name
- NCT07163975
- Testing
- complete pulpotomy, Root canal treatment
- Where
- India
- Volunteers
- 106 people
- Sponsor
- Postgraduate Institute of Dental Sciences Rohtak
Diabetes Mellitus, Type 2
Self Titration With Apidra to Reach Target Study (START)
Primary Objective: The primary objective of this study is to demonstrate non-inferiority of a patient-managed titration algorithm (including blood glucose monitoring) for the addition of a single dose of insulin glulisine at…
- Trial name
- NCT01013571
- Testing
- insulin glargine, Apidra (insulin glulisine)
- Where
- Canada
- Volunteers
- 493 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM
This study is designed to look at the effect of Pioglitazone treatment on the body's ability to burn food in order to produce energy.
- Trial name
- NCT00402012
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Pennington Biomedical Research Center
Supraspinatus Tendinopathy, Type 2 Diabetes Mellitus (T2DM)
Effects of Aerobic Exercise on Shoulder Pain, Disability, and Ultrasonographic Outcomes in Patients With Type 2 Diabetes Mellitus With Supraspinatus Tendinopathy
Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by elevated blood glucose levels over a prolonged period. If left untreated, it can lead to serious and long-term vascular and neurological complications.
- Trial name
- NCT07784543
- Testing
- Conventional Shoulder Rehabilitation, Aerobic Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 24 people
- Sponsor
- Pamukkale University
Type 2 Diabetes
A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)
Glycemic control is a mainstay of diabetes management to reduce the risk of microvascular complications and cardiovascular outcomes in people with type 2 diabetes (T2D).
- Trial name
- REMATCH (NCT06627322)
- Testing
- Dual-combination therapy, Triple-combination therapy, Dexcom G7, Pasta
- Where
- 2 sites in South Korea
- Volunteers
- 5,950 people
- Sponsor
- Kyu Chang Won
Diabetes Mellitus and Heart Failure
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure
- Trial name
- NCT03152552
- Testing
- LIK066, Empagliflozin
- Where
- 106 sites in United States, Argentina and 22 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals